BCEL(Delisted)
AtrecaยทNASDAQ
--
--(--)
BCEL Profile
Atreca, Inc.
A clinical-stage biotechnology company focused on developing novel therapeutics based on interrogation of the active human immune response
835 Industrial Road, Suite 400, San Carlos, CA 94070
--
Atreca, Inc., was incorporated in Delaware on June 11, 2010. The Company is a biopharmaceutical company that utilizes its differentiated platform to discover and develop novel antibody immunotherapeutic agents to treat multiple solid tumor types. The company's lead product candidate, ATRC-101, is a preclinically developed monoclonal antibody with a novel mechanism of action and a target derived from antibodies identified using its discovery platform. Since its establishment, the company has mainly engaged in research and development, raising funds, building management teams and building intellectual property portfolios.
